Please login to the form below

Not currently logged in
Email:
Password:

MannKind

This page shows the latest MannKind news and features for those working in and with pharma, biotech and healthcare.

Sanofi abandons inhaled insulin pact with Mannkind

Sanofi abandons inhaled insulin pact with Mannkind

Sanofi abandons inhaled insulin pact with Mannkind. Poor sales prompt return of Afrezza rights less than a year after its launch. ... In a statement, Mannkind said it will "promptly commence transition discussions" with Sanofi and expects the handover to

Latest news

  • AstraZeneca and its diabetes plans AstraZeneca and its diabetes plans

    A good example of this is MannKind and Sanofi's Afrezza (insulin human), the world's first inhaled that made it to market.

  • Sanofi launches inhaled insulin in US Sanofi launches inhaled insulin in US

    Sanofi launches inhaled insulin in US. Partners with MannKind on only diabetes treatment of its kind. ... The company is working with the drug's inventor MannKind to bring the insulin – known as Afrezza – to people with both type 1 and type 2

  • Sanofi cuts $925m deal for MannKind's inhaled insulin Sanofi cuts $925m deal for MannKind's inhaled insulin

    Sanofi cuts $925m deal for MannKind's inhaled insulin. French company bolsters diabetes business with Afrezza collaboration. ... This inhaler is designed to be used with Mannkind's inhaled insulin Afrezza.

  • Third time lucky as MannKind's inhaled insulin is approved Third time lucky as MannKind's inhaled insulin is approved

    Third time lucky as MannKind's inhaled insulin is approved. US FDA backs new diabetes treatment Afrezza. ... An inhaled formulation of insulin for diabetes could be back on the market shortly after the US FDA approved MannKind's Affrezza.

  • MannKind's inhaled insulin backed for US approval MannKind's inhaled insulin backed for US approval

    MannKind's inhaled insulin backed for US approval. Afrezza finally on course for FDA approval in diabetes after two rejections. ... MannKind's inhaled diabetes therapy Afrezza won the support of an FDA advisory committee yesterday, taking the product to

More from news
Approximately 7 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    It was a big news month for Sanofi, also in the news for terminating its licensing deal with MannKind for Afrezza (inhaled insulin). ... 150. MannKind/ Receptor Life Sciences. Licence, collaboration. Multiple inhaled therapeutic products for conditions

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    The only alternative to injections of the hormone at the moment is Mannkind's inhaled insulin Afrezza - partnered with Sanofi - which has not gained much momentum yet in the marketplace with

  • Going the distance Going the distance

    But it didn't have an easy road to market, with its developer Mannkind having to wait until its third marketing application before receiving approval from the FDA.

  • Pharma deals during August 2014 Pharma deals during August 2014

    As well as the $150m upfront MannKind will receive up to $775m in milestones and a 35% profit share on sales. ... MannKind can only hope. The planned launch is the first quarter of next year.

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    8, 300. MannKind/ Sanofi. Licence. Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • MannKind boosts its senior management team MannKind boosts its senior management team

    California-based MannKind has appointed Matthew Pfeffer as its chief executive officer to replace Alfred Mann, who had held the role ad interim since November. ... Pfeffer will continue to serve as Mannkind's chief financial officer and has also been

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics